The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients

NCT04811924 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Change in methodolody.

Conditions

Keratoconus

Interventions

DRUG: Application of 0.02% MMC over 60 seconds post corneal crosslinking.
DRUG: Corneal crosslinking without the application of 0.02% MMC

Sponsor

Ciusss de L'Est de l'Île de Montréal